// App-Quantinova.ai

: Depletion of Alloreactive T Cells after Haploidentical HSCT: Comparison of Outcomes for Ex Vivo Versus In Vivo Treatment Strategies

Researchers

Presenter

  • Steven Devine

Principal Investigators

  • Stephan Mielke

  • Eduardo Olavarria

  • Bert Tuk

  • Kees Meewisse

  • Andrew Sandler

  • Denis-Claude Roy

Medical Centers

  • Center for International Blood & Marrow Transplant Research, Minneapolis Campus, Minneapolis, MN

  • Department of Internal Medicine II, Wurzburg University Medical Center, Wurzburg, Germany

  • Karolinska Institutet, Karolinska University Hospital and SweBCG, Stockholm, Sweden

  • Hammersmith Hospital, Imperial College, London, United Kingdom

  • TCIM B.V., Willemstad, Netherlands

  • Kite Pharma, Amsterdam, Netherlands

  • Division of Hematology and Medical Oncology, Stem Cell Transplant Program, Department of Medicine, Hopital Maisonneuve-Rosemont, Montreal, Canada

Locations

  • United States

  • Germany

  • Sweden

  • United Kingdom

  • Netherlands

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Graft-versus-host disease

Biomarkers

  • Breakpoint Cluster Region

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02999854

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved